Moreover, a recently developed functional antagonist of S1P4, NXC736 [13], has demonstrated remarkable therapeutic effects against transient ischemic stroke [13], MASH [14], and lung fibrosis [15]. This evidence concerns the gene S1PR4 and metabolic dysfunction-associated steatohepatitis.